Associate Professor ANG Wee Han

(Deputy Head Administration and Student Life)

B.Sc.(Hons), Imperial College of Science, Technology and Medicine, 1992-1995; Ph.D., Ecole Polytechnique Federale de Lausanne, 2003-2007; NUS Overseas Postdoctoral Fellow, Massachusetts Institute of Technology, 2007-2009.

Contact Information

Office: S15-05-01
Tel: (65)-6516-5131 | Fax: (65)-6779-1691
Email: | Personal webpage


ORCID: 0000-0003-2027-356X
ResearcherID: L-2249-2013


Recognition and Achievements

  • EPFL Doctorate Prize, Ecole Polytechnique Fédérale de Lausanne, 2008
  • Member, Asian Biological Inorganic Chemistry Steering Committee, 2016-present
  • Chair, AsBIC-9 Conference in Singapore, 2018


Research Interests

We are interested in the development of therapeutic metallopharmaceuticals and techniques to investigate the interactions of transition metal-based drugs with their biological targets.


Research Highlight

Ref: Chow, M. J.; Alfiean, M.; Pastorin, G.; Gaiddon, C.; Ang, W. H. Apoptosis-Independent Organoruthenium Anticancer Complexes that Overcome Multidrug Resistance: Self-assembly and Phenotypic Screening Strategies. Chem. Sci. 2017, 8, 3641-3649.

Multidrug resistance is a major impediment to chemotherapy and limits the efficacies of conventional anticancer drugs. A phenotypic screening strategy was developed to identify new drug candidates capable of inducing apoptosis-independent programmed cell death and therefore bypass multidrug resistance is to develop.


Teaching Contributions  

  • CM5211 Contemporary Organometallic Chemistry
  • CM5198 Graduate Seminar in Chemistry


Representative Publications  

  • Lee, K. G. Z. Lee; Babak, M. V.; Weiss, A.; Dyson, , P. J.; Nowak-Sliwinska, P.; Montagner, D.; Ang, W. H. Development of an Efficient Dual-action GST-inhibiting Anticancer Platinum(IV) Prodrug, ChemMedChem 2018, in press.
  • Babak, M. V.; Ang, W. H. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy in Metal Ions in Life Sciences vol. 18 - Metallo-Drugs: Development and Action of Anticancer Agents, Jan 2018, pp 1-546.
  • Ong, J. X.; Pang, V. Y. T.; Thng, L. M.; Ang, W. H. Preassembled Coumarin-Rhodamine Scaffold for Ratiometric Sensing of Nitric Oxide and Hypochlorite, Chem. Eur. J. 2017, 24, 1870-1876.
  • Chow, M. J.; Alfiean, M.; Pastorin, G.; Gaiddon, C.; Ang, W. H. Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies , Chem. Sci. 2017, 8, 3641-3649.
  • Chow, M. J.; Licona, C.; Pastorin, G.; Mellitzer, G.; Ang, W. H.; Gaiddon, C. Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance, Chem. Sci. 2016, 7, 4117-4124.
  • Wong, D. Y. Q.; Ong, W. W. F.; Ang, W. H., Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes. Angew. Chem. Int. Ed. 2015, 54, 6483-6487.
  • Wong, D. Y. Q.; Lim, J. H.; Ang, W. H., Induction of targeted necrosis with HER2-targeted platinum(IV) anticancer prodrugs. Chem. Sci. 2015, 6, 3051-3056.
  • Chow, M. J.; Licona, C.; Wong, D. Y. Q.; Pastorin, G.; Gaiddon, C.; Ang, W. H., Discovery and Investigation of Anticancer Ruthenium-Arene Schiff-Base Complexes via Water-Promoted Combinatorial Three-Component Assembly. J. Med. Chem. 2014, 57, 6043-6059.
  • Wong, D. Y. Q.; Yeo, C. H. F.; Ang, W. H., Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents. Angew. Chem. Int. Ed. 2014, 53, 6752-6756.
  • Chin, C. F.; Yap, S. Q.; Li, J.; Pastorin, G.; Ang, W. H., Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(IV) prodrugs. Chem. Sci. 2014, 5, 2265-2270.